|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK
2
When Foreign Investments in Pharma and Biotech Become a National Security Concern
3
Addressing Launch Drift to Optimize Product Launches
4
What FDA's Peptide Decision Means for the Industry
5